Company plans to establish Proof-of-Mechanism and -Biology in patients in immune-inflammatory and oncology indications across its three ongoing clinical programs: IRAK4, IRAKIMiD and STAT3 KT-474 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results